Prognosis of 84 intrahepatic cholangiocarcinoma patients

Chinese Journal of Cancer

Volumn 28, Issue 5, 2009, Pages

  Li, Fang Hua ^a,b   Chen, Xiao Qin ^a,b   Luo, Hui Yan ^a,b   Li, Yu Hong ^a,b   Wang, Feng ^a,b   Qiu, Miao Zhen ^a,b   Teng, Kai Yuan ^a,b   Li, Zhuang Hua ^a,b   Xu, Rui Hua ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chemotherapy; Intrahepatic cholangiocarcinoma; Liver neoplasm; Prognostic factor; Surgical treatment; Survival

Indexed keywords

ALBUMIN; BILIRUBIN; CA 19-9 ANTIGEN; CAPECITABINE; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; GEMCITABINE; MITOMYCIN C; OXALIPLATIN; PIRARUBICIN;

AGED; ALBUMIN BLOOD LEVEL; BILE DUCT CARCINOMA; BILIARY TRACT SURGERY; BILIRUBIN BLOOD LEVEL; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PROGNOSIS; REVIEW; SURGICAL TECHNIQUE; SURVIVAL RATE; TUMOR VOLUME;

EID: 79955748187     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Chen MF. Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment [J]. J Gastroenterol Hepatol, 1999, 14(12): 1144-1149.
2. Jan YY, Yeh CN, Yeh TS, et al. Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital [J]. World J Gastroenterol, 2005, 11(12): 1779-1784.
3. Welzel TM, Mellemkjaer L, Gloria G, et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study [J]. Int J Cancer, 2007, 120 (3): 638-641.
4. Hu M, Wang WL. Study about risk factors for human primary intrahepatic cholangiocarcinoma [J]. Ai Zheng, 1994, 13(2): 156-158. [in Chinese]
5. Anderson CD, Pinson CW, Berlin J, et al. Diagnosis and treatment of cholangiocarcinoma [J]. Oncologist, 2004, 9 (1): 43-57.
6. Kawarada Y, Yamagiwa K, Das BC. Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma [J]. Am J Surg, 2002, 183 (6): 679-685.
7. Chen Q, Wang ZM, Ren ZG, et al. The value of CA19-9 in diagnosing hepatocellular carcinoma and intrahepatic cholangiocarcinoma [J]. Chin J Hepat, 2006, 14 (4): 299-300. [in Chinese]
8. Andreas W, Sonja L, Jochen S, et al. Long-term outcome and prognostic factors of patients with hilar cholangiocarcinoma [J]. World J Gastroenterol, 2007, 13 (9): 1422-1426.
9. DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution [J]. Ann Surg, 2007, 245 (5): 755-762.
10. Kelley ST, Bloomston M, Serafini F, et al. Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy [J]. Am Surg, 2004, 70(9): 743-748.
11. Kajanti M, Pyrhonen S. Epirubicin-sequential methotrexate-5fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study [J]. Am J Clin Oncol, 1994, 17(3): 223-226.
12. Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer [J]. Clin Cancer Res, 2001, 7 (11): 3375-3380.
13. Gebbia V, Giuliani F, Maiello E, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study [J]. J Clin Oncol, 2001, 19(20): 4089-4091.
14. Papakostas P, Kouroussis C, Androulakis N, et al. First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study [J]. Eur J Cancer, 2001, 37(15): 1833-1838.
15. André T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study [J]. Ann Oncol, 2004, 15 (9): 1334-1339.